FDA approves Daratumumab in combination with Pomalidomide and Dexamethasone for relapsed ore refractory multiple Myelomale Myeloma
June 16, 2017 – The U.S. Food and Drug Administration (FDA) has approved the use of daratumumab in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. “We are very pleased to receive the FDA’s decision to approve daratumumab in combination with pomalidomide and dexamethasone. This offers another alternative to patients with multiple myeloma who haven’t seen…..(leggi tutto)